Jjda-042 Jun 2026

| Year | Milestone | |------|-----------| | | Initial hit‑to‑lead campaign within JJDA’s kinase‑focused library. | | 2021 | Lead optimization → JJDA‑042 identified as the most potent, selective candidate. | | 2022 | Patent filing (US 2022/0187645 A1) covering the scaffold, synthetic routes, and therapeutic uses. | | 2023 | First in‑vivo efficacy demonstrated in a JAK2‑driven xenograft model; IND‑enabling toxicology initiated (rat 14‑day repeat dose). | | 2024 (Projected) | Completion of GLP toxicology package; preparation of an IND submission to the FDA (target Q4 2024). | | 2025‑2026 (Projected) | Phase I first‑in‑human trial in patients with advanced MPNs or relapsed AML (dose‑escalation, safety, PK/PD). |

Is this a , a legal case ID , or a chemical compound ? In what region or country did you encounter this code? JJDA-042

The (Is it a fictional item, an internal company SKU, or a typo for another product?) The target audience and tone of the article | Year | Milestone | |------|-----------| | |

Please provide more context, and I'll put together a solid post for you! | | 2023 | First in‑vivo efficacy demonstrated

: Maintain a minimum cable bend radius of at least 10 times the outer cable diameter directly behind the sealing gland to prevent stress concentration.

(Joint Multimodal Data Augmentation) used in machine learning research. Executive Services Directorate (.mil) Could you provide more context